CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 127,684 shares, a decrease of 60.5% from the August 15th total of 323,241 shares. Based on an average daily trading volume, of 99,862 shares, the short-interest ratio is currently 1.3 days. Approximately 2.6% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Guggenheim began coverage on shares of CalciMedica in a report on Thursday, August 20th. They set a “buy” rating for the company. Finally, Wall Street Zen cut shares of CalciMedica from a “sell” rating to a “strong sell” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CalciMedica has an average rating of “Hold” and a consensus target price of $50.00.

CalciMedica Trading Down 6.6%

NASDAQ CALC opened at $1.98 on Friday. The firm has a market capitalization of $13.52 million, a PE ratio of -0.29 and a beta of 0.83. The stock’s 50 day moving average is $3.31 and its 200 day moving average is $3.43. CalciMedica has a twelve month low of $1.91 and a twelve month high of $36.00. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.97. Research analysts forecast that CalciMedica will post -5.25 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Fred A. Middleton bought 49,794 shares of the stock in a transaction dated Thursday, June 25th. The stock was bought at an average price of $4.00 per share, with a total value of $199,176.00. Following the purchase, the director owned 212,654 shares in the company, valued at approximately $850,616. The trade was a 30.57% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 28.25% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

A number of hedge funds and other institutional investors have recently bought and sold shares of CALC. Cetera Investment Advisers increased its stake in shares of CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares in the last quarter. 180 Wealth Advisors LLC boosted its position in shares of CalciMedica by 297.2% in the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of CalciMedica by 45.0% in the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after buying an additional 39,775 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of CalciMedica in the 4th quarter worth approximately $127,000. Finally, Envestnet Asset Management Inc. grew its stake in shares of CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after buying an additional 34,386 shares during the last quarter.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.